| Submission declined on 22 September 2024 by Bhairava7 (talk). Creator not improved this draft per suggested by the other Afc reviewers, I've thought if the Template:Drugbox is added in the draft then it should be acceptable.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Once you save your changes using the "Publish changes" button below, you will be able to resubmit your draft for review by pressing the "Resubmit" button that will appear here. |  |
Comment: You may improve this by adding a Template:Drugbox Pygos (talk) 04:52, 2 September 2024 (UTC)
 | This article may be in need of reorganization to comply with Wikipedia's layout guidelines. (August 2024) |
CT-996 is an once daily oral small molecule GLP-1 agonist developed to treat obesity and type 2 diabetes.[1] It is designed with minimal-to-no beta-arrestin recruitment.[2] In a double-blind, randomized, placebo-controlled Phase I clinical trial participants averaged 6.1 percent placebo adjusted weight loss within four weeks.[3][4][5][6] The drug is being developed by Roche/Genentech after Roche's takeover of Carmot Therapeutics in January 2024.[7][8]
- ^ owenhaskins (2023-10-12). "Carmot's CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetes". Bariatric News. Retrieved 2024-07-28.
- ^ "Clinical Trials | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.
- ^ "Roche - Press release, July 17, 2024". www.roche.com. Retrieved 2024-07-26.
- ^ "CT-996 Demonstrates Significant Weight Loss in Patients with Obesity and Type 2 Diabetes". PharmExec. 2024-07-18. Retrieved 2024-07-26.
- ^ "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-07-28.
- ^ "Handelsblatt". www.handelsblatt.com (in German). Retrieved 2024-07-28.
- ^ Brody, Micaela (2024-01-29). "Carmot Therapeutics Announces Completion of Acquisition by Roche | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.
- ^ Burger, Ludwig (December 4, 2023). "Roche joins race for obesity drugs with $2.7 billion Carmot deal". Reuters. Retrieved July 28, 2024.